The Need for SciBX

Pharmaceutical and biotechnology companies, and the financial community, are being driven to make strategic and investment decisions further and further upstream in the value chain. These decisions concern translational science—the early high-risk work required to create commercial value from new science and technology—and focus on which therapeutic approaches, product pipelines and technology platforms justify continued and future investment. This decision-making pressure is further exacerbated by the accelerating pace and diversity of medical research and the rapidly changing commercial landscape. Understanding the scientific and business context surrounding each piece of new research is the key to lowering the risk associated with these decisions.

SciBX provides an antidote to this information overload by providing a timely, comprehensive and understandable analysis of the most promising science and technology from a science and business perspective. By providing the scientific context, commercial impact and critical next steps for the most promising research on a weekly basis, decision makers and knowledge-management systems will be empowered like never before.

SciBX combines the core skills and methods of BioCentury and Nature Publishing Group that have withstood the test of time.

SciBX enables:

• Management of business/investment risk
• Identification of new projects/assets for investment
• Identification of new partners and emerging competition
• Identification of enabling technology
• Validation of existing technology and research strategy
• More efficient knowledge management

If you need to understand the scientific context, commercial impact and critical next steps of life science research as soon as it is published to more effectively manage your business — then you need SciBX.